Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
about
Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive casesAlpha synuclein and crystallin expression in human lens in Parkinson's disease.Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.Polypoidal Choroidal Vasculopathy.
P2860
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Compatibility of recombinant t ...... n with submacular haemorrhage.
@en
Compatibility of recombinant tissue plasminogen activator
@nl
type
label
Compatibility of recombinant t ...... n with submacular haemorrhage.
@en
Compatibility of recombinant tissue plasminogen activator
@nl
prefLabel
Compatibility of recombinant t ...... n with submacular haemorrhage.
@en
Compatibility of recombinant tissue plasminogen activator
@nl
P2093
P2860
P1476
Compatibility of recombinant t ...... n with submacular haemorrhage.
@en
P2093
Alexa Klettner
Felix Treumer
Johann Roider
Jost Hillenkamp
Simon Grotelüschen
P2860
P304
P356
10.1136/BJOPHTHALMOL-2014-306454
P407
P577
2015-03-04T00:00:00Z